GlassScriptPhysician profile
Raul R Mena
NPI 1609892256
$272.86
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2021: $62.94 · 2022: $44.07.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.76 | 2019-2021 | |
| Seagen INC. | $55.47 | 2019-2022 | |
| Amgen INC. | $40.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.08 | 2019 | |
| Astellas Pharma US INC | $18.58 | 2019 | |
| Kite Pharma, INC. | $17.20 | 2021 | |
| Genentech USA, INC. | $17.10 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
10 companies reported research payments only; those appear in the research section below.
Research and ownership
$13,002.95 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Mena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.